Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 197 entries
Sorted by: Best Match Show Resources per page
Toll-like receptor 9 in breast cancer.

Frontiers in immunology

Sandholm J, Selander KS.
PMID: 25101078
Front Immunol. 2014 Jul 22;5:330. doi: 10.3389/fimmu.2014.00330. eCollection 2014.

Toll-like receptor 9 (TLR9) is a cellular DNA receptor of the innate immune system. DNA recognition via TLR9 results in an inflammatory reaction, which eventually also activates a Th1-biased adaptive immune attack. In addition to cells of the immune...

Cite
Sandholm J, Selander KS. Toll-like receptor 9 in breast cancer. Front Immunol. 2014;5:330doi: 10.3389/fimmu.2014.00330.
Sandholm, J., & Selander, K. S. (2014). Toll-like receptor 9 in breast cancer. Frontiers in immunology, 5330. https://doi.org/10.3389/fimmu.2014.00330
Sandholm, Jouko, and Selander, Katri S. "Toll-like receptor 9 in breast cancer." Frontiers in immunology vol. 5 (2014): 330. doi: https://doi.org/10.3389/fimmu.2014.00330
Sandholm J, Selander KS. Toll-like receptor 9 in breast cancer. Front Immunol. 2014 Jul 22;5:330. doi: 10.3389/fimmu.2014.00330. eCollection 2014. PMID: 25101078; PMCID: PMC4105583.
Copy Download .nbib Format: NLM
Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity.

Oncoimmunology

Kortylewski M, Kuo YH.
PMID: 24800162
Oncoimmunology. 2014 Jan 01;3(1):e27441. doi: 10.4161/onci.27441. Epub 2014 Jan 03.

Proper immunostimulation ("push") and immune checkpoint blockade ("release") are both critical for the efficacy of anticancer immunotherapy. We have recently shown that activating Toll-like receptor 9 (TLR9) while specifically blocking signal transducer and activator of transcription 3 (STAT3) in...

Cite
Kortylewski M, Kuo YH. Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity. Oncoimmunology. 2014;3(1):e27441doi: 10.4161/onci.27441.
Kortylewski, M., & Kuo, Y. H. (2014). Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity. Oncoimmunology, 3(1), e27441. https://doi.org/10.4161/onci.27441
Kortylewski, Marcin, and Kuo, Ya-Huei. "Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity." Oncoimmunology vol. 3,1 (2014): e27441. doi: https://doi.org/10.4161/onci.27441
Kortylewski M, Kuo YH. Push and release: TLR9 activation plus STAT3 blockade for systemic antitumor immunity. Oncoimmunology. 2014 Jan 01;3(1):e27441. doi: 10.4161/onci.27441. Epub 2014 Jan 03. PMID: 24800162; PMCID: PMC4006856.
Copy Download .nbib Format: NLM
Correction: Polygonum cuspidatum and its active components inhibit replication of the influenza virus through toll-like receptor 9-induced interferon beta expression.

PloS one

Lin CJ, Lin HJ, Chen TH, Hsu YA, Liu CS, Hwang GY, Wan L.
PMID: 25860479
PLoS One. 2015 Apr 10;10(4):e0125288. doi: 10.1371/journal.pone.0125288. eCollection 2015.

No abstract available.

Cite
Lin CJ, Lin HJ, Chen TH, et al. Correction: Polygonum cuspidatum and its active components inhibit replication of the influenza virus through toll-like receptor 9-induced interferon beta expression. PLoS One. 2015;10(4):e0125288doi: 10.1371/journal.pone.0125288.
Lin, C. J., Lin, H. J., Chen, T. H., Hsu, Y. A., Liu, C. S., Hwang, G. Y., & Wan, L. (2015). Correction: Polygonum cuspidatum and its active components inhibit replication of the influenza virus through toll-like receptor 9-induced interferon beta expression. PloS one, 10(4), e0125288. https://doi.org/10.1371/journal.pone.0125288
Lin, Chao-Jen, et al. "Correction: Polygonum cuspidatum and its active components inhibit replication of the influenza virus through toll-like receptor 9-induced interferon beta expression." PloS one vol. 10,4 (2015): e0125288. doi: https://doi.org/10.1371/journal.pone.0125288
Lin CJ, Lin HJ, Chen TH, Hsu YA, Liu CS, Hwang GY, Wan L. Correction: Polygonum cuspidatum and its active components inhibit replication of the influenza virus through toll-like receptor 9-induced interferon beta expression. PLoS One. 2015 Apr 10;10(4):e0125288. doi: 10.1371/journal.pone.0125288. eCollection 2015. PMID: 25860479; PMCID: PMC4393289.
Copy Download .nbib Format: NLM
Optically Triggered Immune Response through Photocaged Oligonucleotides.

Tetrahedron letters

Govan JM, Young DD, Lively MO, Deiters A.
PMID: 26034339
Tetrahedron Lett. 2015 Jun 03;56(23):3639-3642. doi: 10.1016/j.tetlet.2015.01.165.

Bacterial and viral CpG oligonculeotides are unmethylated cytosine-phosphate-guanosine dinucleotide sequences and trigger an innate immune response through activation of the toll-like receptor 9 (TLR9). We have developed synthetic photocaged CpGs via site-specific incorporation of nitropiperonyloxymethyl (NPOM)-caged thymidine residues. These...

Cite
Govan JM, Young DD, Lively MO, et al. Optically Triggered Immune Response through Photocaged Oligonucleotides. Tetrahedron Lett. 2015;56(23):3639-3642doi: 10.1016/j.tetlet.2015.01.165.
Govan, J. M., Young, D. D., Lively, M. O., & Deiters, A. (2015). Optically Triggered Immune Response through Photocaged Oligonucleotides. Tetrahedron letters, 56(23), 3639-3642. https://doi.org/10.1016/j.tetlet.2015.01.165
Govan, Jeane M, et al. "Optically Triggered Immune Response through Photocaged Oligonucleotides." Tetrahedron letters vol. 56,23 (2015): 3639-3642. doi: https://doi.org/10.1016/j.tetlet.2015.01.165
Govan JM, Young DD, Lively MO, Deiters A. Optically Triggered Immune Response through Photocaged Oligonucleotides. Tetrahedron Lett. 2015 Jun 03;56(23):3639-3642. doi: 10.1016/j.tetlet.2015.01.165. PMID: 26034339; PMCID: PMC4448726.
Copy Download .nbib Format: NLM
Increased incidence of inflammatory bowel disease: the price of the decline of infectious burden?.

Current opinion in gastroenterology

Feillet H, Bach JF.
PMID: 15703683
Curr Opin Gastroenterol. 2004 Nov;20(6):560-4. doi: 10.1097/00001574-200411000-00010.

PURPOSE OF REVIEW: It is now apparent that the increase in the incidence of autoimmune and allergic diseases in Western countries is explained by the decrease in infections. The question is posed to determine whether a similar explanation can...

Cite
Feillet H, Bach JF. Increased incidence of inflammatory bowel disease: the price of the decline of infectious burden?. Curr Opin Gastroenterol. 2004;20(6):560-4doi: 10.1097/00001574-200411000-00010.
Feillet, H., & Bach, J. F. (2004). Increased incidence of inflammatory bowel disease: the price of the decline of infectious burden?. Current opinion in gastroenterology, 20(6), 560-4. https://doi.org/10.1097/00001574-200411000-00010
Feillet, Hélène, and Bach, Jean-François. "Increased incidence of inflammatory bowel disease: the price of the decline of infectious burden?." Current opinion in gastroenterology vol. 20,6 (2004): 560-4. doi: https://doi.org/10.1097/00001574-200411000-00010
Feillet H, Bach JF. Increased incidence of inflammatory bowel disease: the price of the decline of infectious burden?. Curr Opin Gastroenterol. 2004 Nov;20(6):560-4. doi: 10.1097/00001574-200411000-00010. PMID: 15703683.
Copy Download .nbib Format: NLM
Bacteria, genetics and irritable bowel syndrome.

Expert review of gastroenterology & hepatology

Craig OF, Quigley EM.
PMID: 20528114
Expert Rev Gastroenterol Hepatol. 2010 Jun;4(3):271-6. doi: 10.1586/egh.10.31.

EVALUATION OF: Villani AC, Lemire M, Thabane M et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 138, 1502-1513 (2010). While the pathogenesis of irritable bowel syndrome (IBS) remains to be...

Cite
Craig OF, Quigley EM. Bacteria, genetics and irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2010;4(3):271-6doi: 10.1586/egh.10.31.
Craig, O. F., & Quigley, E. M. (2010). Bacteria, genetics and irritable bowel syndrome. Expert review of gastroenterology & hepatology, 4(3), 271-6. https://doi.org/10.1586/egh.10.31
Craig, Orla F, and Quigley, Eamonn M M. "Bacteria, genetics and irritable bowel syndrome." Expert review of gastroenterology & hepatology vol. 4,3 (2010): 271-6. doi: https://doi.org/10.1586/egh.10.31
Craig OF, Quigley EM. Bacteria, genetics and irritable bowel syndrome. Expert Rev Gastroenterol Hepatol. 2010 Jun;4(3):271-6. doi: 10.1586/egh.10.31. PMID: 20528114.
Copy Download .nbib Format: NLM
Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma.

Oncoimmunology

Rosa R, Damiano V, Formisano L, Nappi L, Marciano R, Veneziani BM, De Placido S, Bianco R.
PMID: 24083076
Oncoimmunology. 2013 Aug 01;2(8):e25123. doi: 10.4161/onci.25123. Epub 2013 May 28.

The mTOR inhibitor everolimus is currently approved for the treatment of renal cell carcinoma (RCC) and several Toll-like receptor 9 (TLR9) agonists, including immunomodulatory oligonucleotides (IMOs), have been tested for their therapeutic potential against advanced RCC. However, no clinical...

Cite
Rosa R, Damiano V, Formisano L, et al. Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma. Oncoimmunology. 2013;2(8):e25123doi: 10.4161/onci.25123.
Rosa, R., Damiano, V., Formisano, L., Nappi, L., Marciano, R., Veneziani, B. M., De Placido, S., & Bianco, R. (2013). Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma. Oncoimmunology, 2(8), e25123. https://doi.org/10.4161/onci.25123
Rosa, Roberta, et al. "Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma." Oncoimmunology vol. 2,8 (2013): e25123. doi: https://doi.org/10.4161/onci.25123
Rosa R, Damiano V, Formisano L, Nappi L, Marciano R, Veneziani BM, De Placido S, Bianco R. Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma. Oncoimmunology. 2013 Aug 01;2(8):e25123. doi: 10.4161/onci.25123. Epub 2013 May 28. PMID: 24083076; PMCID: PMC3782521.
Copy Download .nbib Format: NLM
Association between -1486 T>C and +1174 G>A single nucleotide polymorphisms in TLR9 gene and severity of lupus nephritis.

Indian journal of nephrology

Ramachandran R, Sharma V, Rathi M, Yadav AK, Sharma A, Kohli HS, Sakhuja V, Jha V.
PMID: 22787315
Indian J Nephrol. 2012 Mar;22(2):125-9. doi: 10.4103/0971-4065.97133.

Signaling through Toll-like receptor-9 (TLR9), a mediator of innate immune responses, could have a role in the pathogenesis of systemic lupus erythematosus (SLE). Some studies have shown an association between polymorphisms in the TLR9 gene and disease manifestations. We...

Cite
Ramachandran R, Sharma V, Rathi M, et al. Association between -1486 T>C and +1174 G>A single nucleotide polymorphisms in TLR9 gene and severity of lupus nephritis. Indian J Nephrol. 2012;22(2):125-9doi: 10.4103/0971-4065.97133.
Ramachandran, R., Sharma, V., Rathi, M., Yadav, A. K., Sharma, A., Kohli, H. S., Sakhuja, V., & Jha, V. (2012). Association between -1486 T>C and +1174 G>A single nucleotide polymorphisms in TLR9 gene and severity of lupus nephritis. Indian journal of nephrology, 22(2), 125-9. https://doi.org/10.4103/0971-4065.97133
Ramachandran, R, et al. "Association between -1486 T>C and +1174 G>A single nucleotide polymorphisms in TLR9 gene and severity of lupus nephritis." Indian journal of nephrology vol. 22,2 (2012): 125-9. doi: https://doi.org/10.4103/0971-4065.97133
Ramachandran R, Sharma V, Rathi M, Yadav AK, Sharma A, Kohli HS, Sakhuja V, Jha V. Association between -1486 T>C and +1174 G>A single nucleotide polymorphisms in TLR9 gene and severity of lupus nephritis. Indian J Nephrol. 2012 Mar;22(2):125-9. doi: 10.4103/0971-4065.97133. PMID: 22787315; PMCID: PMC3391810.
Copy Download .nbib Format: NLM
Toll-like receptor-9 is involved in the development of B cell stimulating factor-induced systemic lupus erythematosus.

Experimental and therapeutic medicine

Liu Y, Zhan F, Zhang X, Lin S.
PMID: 29387207
Exp Ther Med. 2018 Jan;15(1):585-591. doi: 10.3892/etm.2017.5411. Epub 2017 Oct 31.

The objective of the present study was to investigate the role of Toll-like receptor (TLR)-9 in B lymphocyte stimulating factor (BLyS)-induced systemic lupus erythematosus (SLE) in mice. The anti-double stranded (ds)DNA antibody titer, levels of complement proteins (C3 and...

Cite
Liu Y, Zhan F, Zhang X, et al. Toll-like receptor-9 is involved in the development of B cell stimulating factor-induced systemic lupus erythematosus. Exp Ther Med. 2017;15(1):585-591doi: 10.3892/etm.2017.5411.
Liu, Y., Zhan, F., Zhang, X., & Lin, S. (2018). Toll-like receptor-9 is involved in the development of B cell stimulating factor-induced systemic lupus erythematosus. Experimental and therapeutic medicine, 15(1), 585-591. https://doi.org/10.3892/etm.2017.5411
Liu, Ying, et al. "Toll-like receptor-9 is involved in the development of B cell stimulating factor-induced systemic lupus erythematosus." Experimental and therapeutic medicine vol. 15,1 (2018): 585-591. doi: https://doi.org/10.3892/etm.2017.5411
Liu Y, Zhan F, Zhang X, Lin S. Toll-like receptor-9 is involved in the development of B cell stimulating factor-induced systemic lupus erythematosus. Exp Ther Med. 2018 Jan;15(1):585-591. doi: 10.3892/etm.2017.5411. Epub 2017 Oct 31. PMID: 29387207; PMCID: PMC5769217.
Copy Download .nbib Format: NLM
The revival of CpG oligonucleotide-based cancer immunotherapies.

Contemporary oncology (Poznan, Poland)

Adamus T, Kortylewski M.
PMID: 29628795
Contemp Oncol (Pozn). 2018 Mar;22(1):56-60. doi: 10.5114/wo.2018.73887. Epub 2018 Mar 05.

The promising results of clinical trials using immune checkpoint inhibitors revived interests in cancer immunotherapy. However, it also became apparent that efficacy of immune checkpoint blockade can benefit from combining it with immunostimulatory strategies. Here, we review prior and...

Cite
Adamus T, Kortylewski M. The revival of CpG oligonucleotide-based cancer immunotherapies. Contemp Oncol (Pozn). 2018;22(1):56-60doi: 10.5114/wo.2018.73887.
Adamus, T., & Kortylewski, M. (2018). The revival of CpG oligonucleotide-based cancer immunotherapies. Contemporary oncology (Poznan, Poland), 22(1), 56-60. https://doi.org/10.5114/wo.2018.73887
Adamus, Tomasz, and Kortylewski, Marcin. "The revival of CpG oligonucleotide-based cancer immunotherapies." Contemporary oncology (Poznan, Poland) vol. 22,1 (2018): 56-60. doi: https://doi.org/10.5114/wo.2018.73887
Adamus T, Kortylewski M. The revival of CpG oligonucleotide-based cancer immunotherapies. Contemp Oncol (Pozn). 2018 Mar;22(1):56-60. doi: 10.5114/wo.2018.73887. Epub 2018 Mar 05. PMID: 29628795; PMCID: PMC5885070.
Copy Download .nbib Format: NLM
Potential Chronotherapeutic Optimization of Antimalarials in Systemic Lupus Erythematosus: Is Toll-Like Receptor 9 Expression Dependent on the Circadian Cycle in Humans?.

Frontiers in immunology

Martínez-García EA, Zavala-Cerna MG, Lujano-Benítez AV, Sánchez-Hernández PE, Martín-Márquez BT, Sandoval-García F, Vázquez-Del Mercado M.
PMID: 30034390
Front Immunol. 2018 Jul 06;9:1497. doi: 10.3389/fimmu.2018.01497. eCollection 2018.

Toll-like receptor 9 (TLR9) belongs to the group of endosomal receptors of the innate immune system with the ability to recognize hypomethylated CpG sequences from DNA. There is scarce information about TLR9 expression and its association with the circadian...

Cite
Martínez-García EA, Zavala-Cerna MG, Lujano-Benítez AV, et al. Potential Chronotherapeutic Optimization of Antimalarials in Systemic Lupus Erythematosus: Is Toll-Like Receptor 9 Expression Dependent on the Circadian Cycle in Humans?. Front Immunol. 2018;9:1497doi: 10.3389/fimmu.2018.01497.
Martínez-García, E. A., Zavala-Cerna, M. G., Lujano-Benítez, A. V., Sánchez-Hernández, P. E., Martín-Márquez, B. T., Sandoval-García, F., & Vázquez-Del Mercado, M. (2018). Potential Chronotherapeutic Optimization of Antimalarials in Systemic Lupus Erythematosus: Is Toll-Like Receptor 9 Expression Dependent on the Circadian Cycle in Humans?. Frontiers in immunology, 91497. https://doi.org/10.3389/fimmu.2018.01497
Martínez-García, Erika Aurora, et al. "Potential Chronotherapeutic Optimization of Antimalarials in Systemic Lupus Erythematosus: Is Toll-Like Receptor 9 Expression Dependent on the Circadian Cycle in Humans?." Frontiers in immunology vol. 9 (2018): 1497. doi: https://doi.org/10.3389/fimmu.2018.01497
Martínez-García EA, Zavala-Cerna MG, Lujano-Benítez AV, Sánchez-Hernández PE, Martín-Márquez BT, Sandoval-García F, Vázquez-Del Mercado M. Potential Chronotherapeutic Optimization of Antimalarials in Systemic Lupus Erythematosus: Is Toll-Like Receptor 9 Expression Dependent on the Circadian Cycle in Humans?. Front Immunol. 2018 Jul 06;9:1497. doi: 10.3389/fimmu.2018.01497. eCollection 2018. PMID: 30034390; PMCID: PMC6043638.
Copy Download .nbib Format: NLM
Mitochondrial DNA-Mediated Inflammation in Acute Kidney Injury and Chronic Kidney Disease.

Oxidative medicine and cellular longevity

Jin L, Yu B, Armando I, Han F.
PMID: 34306320
Oxid Med Cell Longev. 2021 Jun 29;2021:9985603. doi: 10.1155/2021/9985603. eCollection 2021.

The integrity and function of mitochondria are essential for normal kidney physiology. Mitochondrial DNA (mtDNA) has been widely a concern in recent years because its abnormalities may result in disruption of aerobic respiration, cellular dysfunction, and even cell death....

Cite
Jin L, Yu B, Armando I, et al. Mitochondrial DNA-Mediated Inflammation in Acute Kidney Injury and Chronic Kidney Disease. Oxid Med Cell Longev. 2021;2021:9985603doi: 10.1155/2021/9985603.
Jin, L., Yu, B., Armando, I., & Han, F. (2021). Mitochondrial DNA-Mediated Inflammation in Acute Kidney Injury and Chronic Kidney Disease. Oxidative medicine and cellular longevity, 20219985603. https://doi.org/10.1155/2021/9985603
Jin, Lini, et al. "Mitochondrial DNA-Mediated Inflammation in Acute Kidney Injury and Chronic Kidney Disease." Oxidative medicine and cellular longevity vol. 2021 (2021): 9985603. doi: https://doi.org/10.1155/2021/9985603
Jin L, Yu B, Armando I, Han F. Mitochondrial DNA-Mediated Inflammation in Acute Kidney Injury and Chronic Kidney Disease. Oxid Med Cell Longev. 2021 Jun 29;2021:9985603. doi: 10.1155/2021/9985603. eCollection 2021. PMID: 34306320; PMCID: PMC8263241.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 197 entries